How have the shares performed?
Phio Pharmaceuticals Corp. (PHIO) saw an uptrend of 2.34% in the recent trading with $2.19 being its most recent. The current price level -49.77% lower than the highest price of $4.36 marked by the stock while trading over the past 52-weeks, whereas it is 20.33% higher than the lowest price of $1.82 the company dropped to over past 52-weeks. The latest news story on PHIO appeared in PR Newswire under the title “Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches” on Jun-04-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -16.41% below one month high and is +20.33% above of the lowest during that time. Looking into the simple moving average, Phio Pharmaceuticals Corp. (PHIO)’s stock stands at a SMA-50 of $2.30 while that of 5-day is reading $2.13.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and PHIO’s SMA-200 as of now is $2.53.
Phio Pharmaceuticals Corp. Earnings – What Happened With PHIO
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Phio Pharmaceuticals Corp. (PHIO) last released financial results for the quarter that ended 12/30/2020, posting a surprise factor of 2.40% for net revenue.
PHIO – Phio Pharmaceuticals Corp. Stock Earnings Estimates
The perspective of Phio Pharmaceuticals Corp. (NASDAQ:PHIO)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.42 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -0.41.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 13.53 million. PHIO does have institutional investors; and they hold 8.00% of the stock.
Phio Pharmaceuticals Corp. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, PHIO declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Mar 30, 2021, Gsa Capital Partners Llp was the top most holder in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) with an ownership of 0.13 million shares of the company or 0.98% of the stake worth $0.35 million. The filing also reveals Vanguard Group, Inc. (The) as the second largest holder in the company with a control over 0.91% of the outstanding shares. Its stake is worth $0.33 million for having 0.12 million shares in hand.
Geode Capital Management, LLC also came holding a key position in the company during the recent quarter and it now holds 0.65% of the outstanding shares. With this there are now 20 institutions which have possession in PHIO’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Phio Pharmaceuticals Corp. was 6.91 while posting a debt to equity ratio of 0.00. The count was 4.04 for long-term debt to equity ratio.
Phio Pharmaceuticals Corp.’s return on equity, or ROE, is -50.80%, compared to the industry average of -40.21% for Healthcare – Biotechnology. Although this indicates that PHIO fails to use its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Phio Pharmaceuticals Corp. (PHIO), we notice that the stock’s 20-day average volume is at 572,865 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 988,884 shares. And to end, PHIO’s 100-day average volume is 1,248,627 shares with 50% of the long-term indicators pointing towards Sell for the stock.